Benlysta belimumab regulatory update

FDA extended the PDUFA date by 3 months for a BLA from Human Genome for Benlysta belimumab to March 10 from Dec. 9. The human mAb against BLyS (B lymphocyte stimulator protein) is under Priority Revi...